Nature, an expert craftsman of molecules, has generated extensive array of bioactive molecular entities. It persists as an inexhaustible resource for discovery of drugs and supplied enormous scaffold diversification for development into effectual drugs to treat multiple pathological conditions. This review provides an update on the sources, biological, and pharmacological effects of nature's gift, a triterpenoid saponin, tubeimoside-1 which is a major bioactive constituent of the bulb of Bolbostemma paniculatum. Tubeimoside-1 is known to possess various pharmacological properties such as anti-cancer, anti-HIV, and antiinflammatory. Recently, anti-proliferative potential of tubeimoside-1 has been widely studied. The present review article seeks to cover the recent developments of tubeimoside-1's pharmacological position in the arena of herbal drugs, providing an insight into its current status in therapeutic pursuits. This anti-cancer triterpenoid saponin fight cancer progression by induction of apoptosis, cell cycle arrest, and inhibiting metastasis by specifically targeting multiple signaling pathways those are usually deregulated in various cancers. The reported data recommend tubeimoside-1's mutitarget activity in preference to single effect that may perform an imperative role towards developing tubeimoside-1 into potential pharmacological drug.
Introduction
Natural products (NPs) have been an excellent and inexhaustible source of enormous chemical diversification driving pharmaceutic industry over the antecedent century [1] . In spite of synthetic chemistry approaches as a vehicle to drug discovery, contribution of plant-derived NPs for the cure and prevention of ailments is still enormous [2] . The term "Natural products" covers chemical compounds that are derived from natural sources [3] . Discovered NPs have effectively played crucial role in promoting human health as potent drugs of choice due to their efficacy and safety. These naturally occurring chemical compounds have valuable drug-like characteristics and have capability to interact with diverse cellular targets [4] . Presently, plant-based drug discovery is chiefly dependent upon bioactivity-directed fractionation techniques which leads to the isolation of imperative drugs such as camptothecin and paclitaxel etc. [2] .
First evidence of sophisticated medicinal utilization of plants dates back to 2600 BC consisting of 1000 plant-derived medicines in Mesopotamia. Traditional Chinese medicine (TCM) has been widely reported as an effective medicinal system over centuries. However, rational plant-based drug discovery initiated at the outset of 19th century with publication on isolation, crystal structure, crystallization, and bioactivities of analgesic compounds from opium plant which triggered the further investigation on medicinal herbs and natural products [5] . Over 20,000 captivative natural products have been explored in the past 50 years. From these flourishing struggles, 12 agents in clinical trials and 9 approved drugs have been disclosed [6] . It is reported by researchers that 74% of the most crucial drugs and 50% of drugs that are being used in clinics are derived from medicinal plants [7] . In accordance to a record from WHO, 80% of the population globally still dependent on plant-based drugs. Accordingly, this approach of drug discovery still represents far-reaching domain, hitherto unplumbed, where an extensive research could supply imperative leads against cellular targets in biological systems [8, 9] .
Various pharmacological investigations on medicinal plants have affirmed their authenticity as potential source of anti-cancer [10] [11] [12] [13] [14] , anti-inflammatory [15] , anti-oxidant [16] , and neuroprotective agents [17] .
Saponins are an extensive family of amphiphilic glycosides of triterpenes and steroids naturally abundant in medicinal herbs, plants, and some of the marine organisms. Due to immense diversity in structures of aglycones and sugar chains, saponins exhibit wide spectrum of pharmacological and biological activities and have performed major role as active principles in folk medicine [18] . Tubeimoside-1, a triterpenoid saponin extracted from Bolbostemma paniculatum, has been known to exhibit various pharmacological properties such as anti-tumor, anti-inflammatory [19] , and anti-HIV effects [20] .
To date, no review article is available on the pharmacological activities of tubeimoside-1. This review intends to emphasize on the researches related to pharmacological and biological effectiveness of tubeimoside-1. This will facilitate the understanding of researchers for tubeimoside-1's pharmacological position in drug discovery, thus, representing areas for further research. The literature is screened through various e-sites including Springer Link, PubMed, Elsevier Science Direct, Scopus and other relevant Biological activities of tubeimoside-1: The bioactive naturally occurring saponin, tubeimoside-1, has been reported to exhibit various pharmacological activities such as anti-tumor, antiinflammatory and anti-HIV effects (Figure 1 ). Multiple in vivo and in vitro studies have been conducted to elucidate the medicinal properties of tubeimoside-1 and its mechanism of action revealing it as potential anti-cancer agent.
Anti-cancer activities:
Cancer is a multi-faceted pathological condition encompassing metabolic, genetic, and signaling defects that markedly upset normal homeostasis of cellular growth and death [25] . Current treatments opportunities for this deadly disease are based on chemotherapy/synthetic drugs that have delimited clinical success because they are invariably associated with high toxicity and are expensive, thus, arousing the urgent need to find safe and inexpensive alternatives [8] . Cancer chemoprevention by naturally occurring bioactive compounds such as phytochemicals, vitamins, and minerals has turned up as pragmatic and promising access to diminish the burden of cancer and this approach is gaining attentiveness day by day. Unlike pharmaceutic drugs being monotargeted, these naturally occurring compounds are multitarget having capability to regulate cellular growth and proliferation [7] .
Currently, more than 60% of the commercial anti-cancer drugs have been originated from natural sources encompassing microorganism, marine organisms, and plants [26] . Researchers have declared that dietary consumption of fruits, vegetables, and other naturally occurring foodstuffs reduce the rate of cancer incidences to 20% and approximately 20,000 deaths annually [27] . Now a days, there is an increasing concern in screening of plant extracts for drug development against cancer because naturally occurring phytochemicals have pronounced capability to inhibit carcinogenesis by interfering multiple signaling pathways that are fundamental to cancer progression [28] .
Secondary metabolites from plants such as polyphenols, alkaloids, and terpenes have been well documented for their anti-cancer activity [29] [30] [31] . Until now, approximately 55,000 terpenes have been isolated but only a limited fraction has been characterized for their anti-cancer potential. Saponins and sesquiterpene lactones as major classes of terpenes have been reported as anti-cancer agents against wide range of cancer types. Triterpenoid saponins have been well-documented to possess multiple pharmacological properties such as anti-cancer, anti-oxidant, anti-bacterial, and neuroprotective. Tubeimoside-1 is an oleanane type triterpenoid saponin [23] having two chains of sugar at C-3 and C-28. Tubeimoside-1 has been comprehensively studied and affirmed to possess compelling anti-cancer properties against wide range of cancer types such as hepatoma, cervical carcinoma, glioma, ovarian cancer, choriocarcinoma, and lung cancer [25] (Figure 2 ).
Tubeimoside-1 and cell cycle arrest: Since, rapid and uncontrolled cellular division is a key trait of cancer cells [32] , therefore, natural bioactive compounds inhibiting mitosis or controlling cell cycle are proved to be attractive candidates for novel anti-cancer therapies [33, 34] . Substantial advances that have been made to figure out molecular mechanism essential in regulating cell cycle have affirmed that natural chemotherapeutic agents are important for enhancing the competency of targeted therapeutics. These naturally occurring compounds have promising capability to inhibit the functioning of cyclin dependent kinases, and cyclins along with numerous enzymes and protein factors involved in regulation of cell cycle leading cells toward controlled state [35] .
Tubeimoside-1 has been reported to arrest cell cycle in various cancerous cells at G2/M and G0/G1 phase's. In human HepG2 cells, it has been recognized to interfere with G2/M checkpoint and causing arrest [36, 37] . HeLa cells treated with tubeimoside-1 displayed chromatin condensation, nuclear shrinkage, and DNA fragmentation along with G2/M cell cycle arrest [22] . Cytoplasmic sequestration of Cip1/p21, Cdc25C induction with dyspolymerization of tubulin contributed to tubeimoside-1-induced G2/M phase arrest coincided with reduction in G0/G1 phase in HeLa cells. Furthermore, Cdc2 and cyclin B1 expression was inhibited while Chk2 phosphorylation was enhanced [38] ( Figure  4 ). Nuclear proteomic study in EC109 cells has declared the presence of modified proteins linked with cellular proliferation and mitochondrial function. These molecular events stimulated by tubeimoside-1 were associated with p21-cyclin B1/cdc2 complexassociated G2/M phase arrest [39] . JEG-3, T24, and A375 cells displayed significant G2/M phase arrest followed by the treatment Tubeimoside-1 as a potential natural cancer killer Natural Product Communications Vol. 13 (5) 2018 645 
Up-regulation ↑, Down-regulation ↓, Inhibition ┴, Activation Act , Myeloid cell leukemia 1 (Mcl-1), Bcl-2-associated x protein (Bax), B-cell lymphoma 2 (Bcl-2), Activator protein 1 (AP-1), c-Jun N-terminal kinase (JNK), Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), Mitogen-activated protein kinase (MAPK), Tumor necrosis factor-α (TNF-α), Apoptosis signalregulating kinase 1 (ASK-1), Reactive oxygen species (ROS), Cyclooxygenase-2 (COX-2), Fas ligand (FasL), Mammalian target of rapamycin (mTOR), Chemokine CXC motif receptor 4 (CXCR4), Cyclin-dependent kinase 2 (Cdk2), Checkpoint kinase 2 (Chk2), Cyclin-dependent kinases (Cdc2, Cdc25C), Cyclin-dependent kinase inhibitor p21 (Cip1/p21), Glucose-regulated protein 78/immunoglobulin heavy chain binding protein (GRP78/Bip), Extracellular signal-regulated kinase (ERK), C/EBP homologous protein (CHOP) of tubeimoside-1 [40] [41] [42] . An investigation on anti-cancer activity against SKOV-3 cells has proved that pro-apoptotic property of tubeimoside-1 was accredited to G2/M phase arrest [43] . It has capability to induce cell cycle arrest at G1 phase in breast MDA-MB-231 cells [44] . Tubeimoside-1 lead DU145 and P3 cells to G0/G1 phase arrest mediated by enhanced expression of p53 through its downstream effector p21 and reduced expression of cdk2 along with cyclin E [45] (Figure 3 ). G2/M phase arrest by tubeimoside-1 in A549 and PC9 cells was linked with reduction in cyclin B1 expression and increased p21 and p15 levels [46] .
It can be concluded that tubeimoside-1 arrest cell cycle at G2/M phase but whether in G2 or M phase should be investigated. Furthermore, it would be interesting to investigate the mechanism by which tubeimoside-1 arrested cell cycle in prostate cells at G0/G1 phase as in case of other cancer cells it is generally arresting cells at G2/M or G2 phase. So, extensive studies are yet mandatory to fully understand molecular mechanism by which tubeimoside-1 regulates cell cycle or stimulates cell cycle arrest.
Tubeimoside-1 and apoptosis: Apoptosis is extremely systematized mode of cell death involving multiple intracellular events operating together to demilitarize dangerous or unwanted cells from the body [47] . Apoptosis is widely recognized as a crucial constituent of various biological processes such as immune functioning, embryonic development, cell death, and normal cellular turnover. Improper or disrupted apoptosis is a causative agent for many pathological conditions as autoimmune diseases, neurodegenerative conditions and numerous cancer types [48] .
It is well-established fact that programmed cell death or apoptosis proceeds via specific pathways; extrinsic death or receptor pathway, intrinsic or mitochondrial pathway [49] . These pathways induce the activation of pioneering caspases, which in turn activates effector caspases. These effector caspases are crucial prosecutioners of cell death in programmed way [50] . Accumulated evidences by researchers commend that natural compounds have promising capability to prompt apoptosis leading cancerous cells to the road of death by modulating variety of cellular factors in extrinsic or intrinsic apoptotic pathways [13, 14, [51] [52] [53] [54] [55] .
Tubeimoside-1 has turned up as novel paradigm for multi-targeted chemotherapeutic capability [38] . Anti-cancer property of tubeimoside-1 has been proclaimed to be affiliated with apoptosis induction via caspase family activation, reactive oxygen species accumulation/oxidative stress, regulation of signaling via TNF-α, activation of proapoptotic proteins (Bax, Bak), down-regulation of anti-apoptotic proteins (Mcl-1, Bcl-2), Fas and Fas ligand activation [36, [56] [57] [58] , COX-2 inhibition [59] , modulating MAPK pathway (enhancing p38 MAPK and JNK phosphorylation, activating ERK1/2), repressing Wnt/β-catenin signaling pathway [60] , mitochondrial dysfunction, NF-κB inhibition, AP-1, p53 regulation [36, 40, 46, 61] , inducing cytochrome c release and ER stress [62] [63] [64] . Cell cycle is distributed into four distinctive phases (G1, S, G2, and M) respectively. As shown, tubeimoside-1 has capability to arrest various cancer cells at G2/M and G0/G1 phases. Tubeimoside-1 is reported to up-regulate p15 and p21. During cell cycle, cyclin D isoform combines with Cdk4/6 to direct the progression of cell into G1 phase. Proceeding further cyclin E and Cdk2 found to be active at G1-S phase transition. Tubeimoside-1 is reported to down-regulate the expression of cyclin E and Cdk2. Cyclin A combines with Cdk2 and Cdk1 during S phase progression and G2 phase respectively. However, no effect of tubeimoside-1 has been reported on cyclin A. Cyclin B and Cdk1 complex is crucial for entry of cell into mitosis. Here, tubeimoside-1 is reported to modulate cyclin B and Cdk1 complex formation thus blocking G2/M transition.
Tubeimoside-1 and NF-κB signaling pathway NF-κB refers to a domain of transcriptional factors which regulate the expression of huge number of genes concerning to development, proliferation, survival, immune responses, angiogenesis, metastasis, and invasion. It is widely sanctioned as most common signaling regulator of cancer initiation and progression, promoting growth of tumor cells via expression of various growth regulating genes such as cyclin E, cyclin D1, D2, D3, and CDK2. Thus, targeted disruption of NF-κB signaling pathway is a tempting approach to combat cancer [65] .
Phytochemicals have been reported to stimulate apoptotic cell death by modulating the activity of tumor promoting factor NF-κB [66] . Tubeimoside-1 has capability to effectively inhibit apoptotic signaling molecule NF-κB via its upstream signaling factor TNF-α modulation in HepG2, A549, and PC9 cells [36, 46] . Tubeimoside-1 down-modulated the expression of CXCR4 (a chemokine receptor which promotes tumor metastasis) in breast cancer cells by suppressing NF-κB binding activity to CXCR4 promoter as various transcriptional factors such as NF-κB, PPAR-γ, and HIF-1α mediate the up-regulation of CXCR4 in cancerous cells [67] . After exposure of JEG-3 cells to tubeimoside-1, NF-κB p65 protein factors displayed explosive reduction in nucleus and a significant increment in cytoplasm indicating that tubeimoside-1 significantly debilitated NF-κB activation and translocation (Figure 4 ) [40] . Induction of IκBα expression by tubeimoside-1 in NCI-H460 cells commend that it could inhibit NF-κB expression because it is well-established fact that IκB proteins such as IκBα, IκBε and IκBβ serve as canonical inhibitors for NF-κB pathway [68, 69] . Though several studies have reported that tubeimoside-1 induces apoptosis via inhibition of NF-κB but whether, tubeimoside-1 has direct effect on NF-κB signaling pathway or via its up-stream signaling pathway JAK or STAT-3 still needs to be investigated by researchers.
Tubeimoside-1 and MAPK and PI3K/Akt signaling pathway:
Mitogen activated protein kinase (MAPK) pathway environ various key signaling constituents along with phosphorylation reactions which perform an imperative role in tumor development. This pathway is comprised of four key signaling domains; c-Jun N terminal kinase (JNK), MAPK/ERK family, Big MAP kinase-1 (BMK-1), and p38 MAPK. When activated, these kinases conduct extracellular cues that govern cellular growth, proliferation, differentiation, metastasis, and apoptosis. Therefore, MAPK related pathways epitomize a novel target for cancer prevention [70, 71] . The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is widely considered as imperative player for cancer initiation and progression. Over activation of this signaling pathway is associated with numerous cancer types. Thus, targeting Akt pathway is a promising approach to combat cancer [72] .
Triterpenoids have been reported to prompt apoptosis in cancerous cells by modulating MAPK and Akt pathways [73, 74] . Administration of tubeimoside-1 suppressed the activity of JNK and p38 MAPK signaling pathway via dampening phosphorylation level of JNK and p38 MAPK, thus, suggesting that it have potential to inhibit growth in PC9 and A549 lung cancer cells [46] . Anti-cancer activities of tubeimoside-1 proceed through enhanced p38 MAPK phosphorylation along with reduced ERK1/2 and Akt phosphorylation in JEG-3 cells [40] . Tubeimoside-1 enhanced the expression of p-JNK in HepG2 cells [36] . ASK-1 is a representative of MAPK pathway activated by phosphorylation in response to ER stress, and oxidative stress. When once activated, ASK-1 induce the activation of JNK and p38 MAPK via phosphorylation (Figure 4) . Tubeimoside-1 engendered phosphorylation of ASK-1 along with its downstream target p38 and JNK dose-dependently [45] . Pro survival oncoproteins ERK1/2, Akt are known to favor cellular survival signals via NF-κB activation. Results from this study commend that NF-κB inhibition would be mediated via promoting phosphorylation of p38 MAPK while inhibiting ERK1/2, Akt phosphorylation. However, to precisely figure out this mechanism further experimental investigations are recommended [40] . In addition, there is lack of data regarding to multiple splice variants of JNKs such as whether tubeimoside-1 targets JNK1 or JNK2 which should be addressed by researchers.
Anti-inflammatory activity:
Inflammation is a complex process occurring in response to tissue damage or injury inflicted by infectious or other stimuli. Inflammation is associated with the outset of various pathological conditions such as autoimmune diseases, cancer progression, and cardiovascular diseases. Negative and side effects affiliated with non-steroidal type anti-inflammatory drugs (NSAIDs) arouse a need to find out safe alternatives [77] [78] [79] . Tubeimoside-1has been reported to mitigate inflammation in LPSstimulated in vitro and in vivo models by inhibiting the generation of pro-inflammatory cytokines such as TNF-α IL-6, and IL-1β (Figure 4) . Pretreatment of tubeimoside-1 has capability to extenuate the progression of pulmonary edema, inflammatory cells 648 Natural Product Communications Vol. 13 (5) 2018 Zafar et al.
infiltration, and histological severities in LPS-stimulated lung injury model. Tubeimoside-1 employs its anti-inflammatory effect via suppressing p38 MAPK signaling pathway and IκB activation in in vivo model [80] . Even though, tubeimoside-1's utilization has been reported as traditional anti-inflammatory agent still there is very limited data regarding to anti-inflammatory potential so it might be interesting to conduct further mechanistic studies regarding to this effect of tubeimoside-1.
Anti-HIV activity:
As the risk of human immunodeficiency virus (HIV) disease continues to rise up, effective treatment strategies are required to cure infected patients. Although, antiretroviral therapy contributes to stable viral abolition, still it is not devoid of unwanted after affects. Plant extracts and plant derived compounds have promising potential to turn into novel drug leads with anti-HIV potential [81] . Triterpenoid saponins have been known to exhibit anti-HIV potential [82] .
Tubeimoside-1 has potency to inhibit HIV core protein p24 generation and cytopathogenesis arbitrated by HTLV-IIIB with an effective concentration of 24.1 and 22.9 micrograms.mL -1 respectively. From this study, it is figured out that tubeimoside-1 has inhibitory activity against HIV infection isolates and it could be a promising candidate agent to treat AIDS [20] .
In vivo studies and biosafety profiles: Tubeimoside-1 has been studied in vivo in tumor metastasis mouse model induced by injecting MDA-MB-231-Luc cells into tail vein of female nude mouse. Intraperitoneal administration of 20 mg/kg tubeimoside-1 for one month resulted in CXCR4-mediated tumor metastasis suppression [67] . Results from in vivo investigation of tubeimoside-1 in BALB/c mice have declared that it not only has the capability to inhibit tumor growth but more interestingly it also prolonged the life expectancy of tumor bearing mouse. Administration of 3, 4 mg/kg tubeimoside-1 for 16 and 14 days respectively resulted in 71.5% and 64% inhibition in tumor growth [21] . Tubeimoside-1 has ability to exert its anti-inflammatory effect via suppressing p38 MAPK signaling pathway and IκB activation in LPS-induced in vivo lung injury model [80] . Taken together, it is recommended that multiple in vivo models should be employed to assure efficacy of tubeimoside-1 as chemotherapeutic and anti-inflammatory agent.
Tubeimoside-1 comes out to be interested compound as it combines effective chemotherapeutic effect with low toxicity generally as compared to other triterpenoid saponins. According to Lijian et al., after chronic treatment of tubeimoside-1 for 18 weeks, no histological detachable impacts on skin of mouse were observed [21] . However, safety dosage and efficacy of tubeimoside-1in targeted therapeutic domains yet to be executed in future. Furthermore, studies related to identification of genotoxicity, reproductive toxicity, nephrotoxicity and hepatotoxicity need to be investigated by researchers. Conclusions and future perspectives: In this review, we have spotlighted the progress of tubeimoside-1 as anti-cancer, antiinflammatory, and anti-HIV agent. Compiled data from multitudinal studies have provided compelling evidences for potent role of tubeimoside-1 in treatment of various cancer types. Tubeimosde-1 possess wide spectrum of toxicity against broad range of human cancer cell lines. After the critical analysis of reported studies, we have observed that this compound show most potent activity against brain cancer cell line A-172 with IC 50 value 0.1 μM but no mechanistic studies have been conducted yet. So, it would be very interesting to investigate about mechanism of action of tubeimoside-1 against this cancer because brain cancers are among the deadliest and incurable ones. Furthermore, it will also be captivating to investigate that whether tubeimoside-1 can cross blood brain barrier or not. Tubeimoside-1's mechanism of action proceeds via modulation of multiple signaling pathways such as PI3K/Akt, MAPK, Wnt/β-catenin, and NF-κB and pathways, which are usually de-regulated in cancer cells and are also affiliated with drug resistance. As it is one of the chemical constituents of Chinese folk medicine "Tu Bei Mu" which is mostly utilized to treat tumors, tubeimoside-1 might turn up as safe chemotherapeutic drug candidate. In addition, tubeimoside-1 exhibits acceptable in vitro potency and selectivity strengthening that multiple in vivo models and clinical trials should be employed to assure its efficacy for the therapeutic indication. Although tubeimoside-1 is reported to be a potent drug candidate but which structural moieties are actually responsible for its activity should be investigated. It would also be worthwhile to investigate structure-activity relationship of tubeimoside-1 in several activities such as anti-cancer and antiinflammatory. As it is evident that naturally occurring bioactive molecules will continue to be an imperative focus for research in chemical biology, so, the yield of naturally occurring compounds has its own importance. Bioassay guided fractionation of n-BuOH fraction of Bolbostemma paniculatum led to the isolation of 25 mg tubeimoside-1 from 50 kg plant material [83, 84] . Isolation and characterization of such minute quantities of bioactive compound, tubeimoside-1, from complex mixture will persist as a laborintensive and challenging process. So, it would be very interesting for organic chemists to work on its chemical synthesis, as no one has still attempted to synthesize it in the laboratory. Even though tubeimoside-1 has been isolated from n-BuOH fraction but whether its yield can be improved by changing solvents or it has better solubility in other solvents should be investigated. In the light of antecedent observations, it can be speculated that tubeimoside-1 may become a novel lead compound for anti-cancer drugs but further experimentation, medicinal chemistry, and preclinical studies are yet mandatory to elucidate full spectrum of its pharmacological activities. It is hoped that compiled data will pave a way for researchers towards establishment of this compound into promising anti-cancer drug in the years to come.
